+41 91 682 20 40
info@elixi-int.com
Reserved Area
Login
Register
Request Document
Send Document
Home
About Us
Services
Quality
News
Case Studies
Contact
Online Store
Let's talk
info@yourwebsite.com
+1 (555) 123-4567
Search
Neurotrophic Tyrosine Receptor Kinase
14 August 2020
Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
by Elixi
9 August 2019
Vitrakvi (larotrectinib), first ‘histology-independent’ treatment for solid tumours with a specific gene mutation
by Elixi